T cell |
Inhibit T-cell activation |
CD39, CD73 |
Various cancers exosomeal |
[17] |
PD-L1 |
Glioblastoma EVs |
[18] |
Inhibit T-cell proliferation |
TGF-β |
Breast cancer cell exosomal |
[16] |
Promote T-cell apoptosis |
Fas L |
Ovarian cancer exosomal |
[23] |
Dysfunction; inhibit Th1 and Th17 differentiation; suppress T-cell functions |
miR-24-3p, miR-891a, miR-106a-5, miR-20a-5p, miR-1908 |
Nasopharyngeal carcinoma exosomal |
[26] |
PD-L1 |
Melanoma/lung/breast cancer exosomal |
[30] |
miR-23a-3p |
Hepatocellular carcinoma cells exosomal |
[29] |
Activate Tregs; promote Treg expansion |
CCL20 |
Nasopharyngeal carcinoma exosomal |
[33] |
TGF-β |
Colorectal cancer cell EVs |
[32] |
miR-214 |
Lewis lung cancer and human embryonic kidney cell line microvesicles |
[34] |
miR-24-3p |
Nasopharyngeal carcinoma (NPC) cell lines and patient sera exosomal |
[25] |
Enhance the inhibitory effect of MDSCs on γδT cells |
miR-21 |
Oral squamous cell carcinoma (OSCC) cell lines Cal-27 and SCC- 9 exosomal |
[36] |
B cell |
Suppression function |
Tumor antigen |
Pancreatic cancer exosomal |
[38] |
— |
Mycoplasma infects tumor cells exosomal |
[40] |
Promote Breg expansion |
— |
Esophageal cancer microvesicles |
[39] |
Macrophages |
Formation of inflammatory environment before metastasis |
miR-21; miR-29a |
Lung cancer cell lines A549 and SK-MES exosomal |
[43] |
Annexin A2, IL-6, TNF-α |
Breast cancer exosomal |
[44] |
GCSF, IL-6, IL-8, IL-1β, CCL2, TNF-α |
Breast cancer exosomal |
[63] |
Induce the polarization of macrophage to M2 phenotype |
miR-222-3p |
Epithelial ovarian cancer Skov-3 cells exosomal |
[48] |
— |
Glioblastoma stem cell exosomal |
[50] |
— |
Lung cancer cell exosomal |
[49] |
DCs |
Inhibit antigen presentation function |
miR-203 |
Pancreatic cancer cell panc-1 exosomal |
[53] |
miR-212-3p |
Pancreatic cancer cell line PANC-1, SW1990, BxPC-3 exosomal |
[52] |
Change the direction of differentiation |
— |
Breast cancer/lung cancer exosomal |
[54] |
— |
Melanoma/colorectal cancer exosomal |
[55] |
NK cell |
Down-regulate the expression of the activating receptor NKG2D |
MICA*008 |
Human cervical cancer exosomal |
[58] |
NKG2Dligand |
Leukemia/lymphoma exosomal |
[64] |
Inhibit NK cell function; impair NK cell-mediated cytotoxicity |
TGF-β |
Acute myeloid leukemia exosomal |
[23] |
miR-92b |
Serum exosomal from rat model of orthotopic liver tumor |
[61] |
miR-23a;TGF-β |
Multiple tumor cells derived microvesicles |
[59] |